相似文献
1
Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction.药物遗传学与抗精神病药：疗效和副作用预测。
Expert Opin Drug Metab Toxicol. 2011 Jan;7(1):9-37. doi: 10.1517/17425255.2011.532787.
2
Pharmacogenetics of antipsychotics: recent progress and methodological issues.抗精神病药物的药物遗传学：最新进展和方法学问题。
Expert Opin Drug Metab Toxicol. 2013 Feb;9(2):183-91. doi: 10.1517/17425255.2013.736964. Epub 2012 Dec 1.
3
Pharmacogenetics and antipsychotics in the light of personalized pharmacotherapy.基于个体化药物治疗的药物遗传学与抗精神病药物。
Psychiatr Danub. 2010 Jun;22(2):335-7.
4
Association of Genetic Variants of Dopamine and Serotonin In Schizophrenia.精神分裂症中多巴胺和血清素遗传变异的关联。
Arch Med Res. 2020 Jan;51(1):13-20. doi: 10.1016/j.arcmed.2019.12.011. Epub 2020 Feb 18.
5
Personalized antipsychotic treatment: the adverse effects perspectives.个体化抗精神病治疗：不良反应视角。
Psychiatr Danub. 2010 Jun;22(2):329-34.
6
Pharmacogenetics and schizophrenia.药物遗传学与精神分裂症
Psychiatr Clin North Am. 2007 Sep;30(3):417-35. doi: 10.1016/j.psc.2007.04.004.
7
Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research.精神分裂症的药物遗传学和药物基因组学：过去十年研究综述
Mol Psychiatry. 2007 Aug;12(8):707-47. doi: 10.1038/sj.mp.4002009. Epub 2007 Jun 5.
8
Pharmacogenetics and antipsychotic treatment response.药物遗传学与抗精神病药物治疗反应
Pril (Makedon Akad Nauk Umet Odd Med Nauki). 2015;36(1):53-67.
9
Pharmacogenetics of Antipsychotic Treatment in Schizophrenia.抗精神病药物治疗精神分裂症的药物遗传学。
Methods Mol Biol. 2022;2547:389-425. doi: 10.1007/978-1-0716-2573-6_14.
10
Catechol-O-Methyltransferase Val158Met Polymorphism and Clinical Response to Antipsychotic Treatment in Schizophrenia and Schizo-Affective Disorder Patients: a Meta-Analysis.儿茶酚-O-甲基转移酶Val158Met多态性与精神分裂症和分裂情感性障碍患者抗精神病治疗的临床反应：一项荟萃分析。
Int J Neuropsychopharmacol. 2016 Apr 29;19(5). doi: 10.1093/ijnp/pyv132. Print 2016 May.
引用本文的文献
1
Molecular Underpinning of Treatment-Resistant Schizophrenia: A Putative Different Neurobiology from Treatment-Responsive Schizophrenia.难治性精神分裂症的分子基础：与反应性精神分裂症不同的假定神经生物学机制
Int J Mol Sci. 2025 Sep 4;26(17):8598. doi: 10.3390/ijms26178598.
2
Predictive Role of Serotonin Receptor (5HTR2A) and Dopamine Receptor (DRD2) gene polymorphisms in risperidone-induced weight gain and hyperprolactinemia in patients with schizophrenia.血清素受体（5HTR2A）和多巴胺受体（DRD2）基因多态性在精神分裂症患者利培酮所致体重增加和高泌乳素血症中的预测作用
Eur J Clin Pharmacol. 2025 Jun;81(6):899-905. doi: 10.1007/s00228-025-03835-5. Epub 2025 Apr 2.
3
Unidentified genotype does not affect pharmacological treatment for patients with first episode psychosis.基因型不明并不影响首发精神分裂症患者的药物治疗。
J Psychopharmacol. 2024 Dec;38(12):1111-1121. doi: 10.1177/02698811241279022. Epub 2024 Sep 29.
4
Clinical effects of CYP2D6 phenoconversion in patients with psychosis.精神疾病患者 CYP2D6 表型转化的临床效果。
J Psychopharmacol. 2024 Dec;38(12):1095-1110. doi: 10.1177/02698811241278844. Epub 2024 Sep 23.
5
Pharmacogenetics of Long-Term Outcomes of Schizophrenia Spectrum Disorders: The Functional Role of CYP2D6 and CYP2C19.精神分裂症谱系障碍长期预后的药物遗传学：CYP2D6和CYP2C19的功能作用
J Pers Med. 2023 Sep 4;13(9):1354. doi: 10.3390/jpm13091354.
6
Dual orexin/hypocretin receptor antagonism attenuates NMDA receptor hypofunction-induced attentional impairments in a rat model of schizophrenia.双重食欲素/下丘脑分泌素受体拮抗剂可减轻 NMDA 受体功能低下诱导的精神分裂症大鼠模型的注意力损伤。
Behav Brain Res. 2023 Jul 26;450:114497. doi: 10.1016/j.bbr.2023.114497. Epub 2023 May 16.
7
Deep Brain Stimulation in the Treatment of Tardive Dyskinesia.深部脑刺激治疗迟发性运动障碍
J Clin Med. 2023 Feb 27;12(5):1868. doi: 10.3390/jcm12051868.
8
Dual orexin/hypocretin receptor antagonism attenuates attentional impairments in an NMDA receptor hypofunction model of schizophrenia.双重食欲素/下丘脑泌素受体拮抗作用可减轻精神分裂症NMDA受体功能减退模型中的注意力障碍。
bioRxiv. 2023 Feb 5:2023.02.05.527043. doi: 10.1101/2023.02.05.527043.
9
Antipsychotic drug-aripiprazole against schizophrenia, its therapeutic and metabolic effects associated with gene polymorphisms.抗精神分裂症药物-阿立哌唑，其治疗和代谢作用与基因多态性相关。
Pharmacol Rep. 2023 Feb;75(1):19-31. doi: 10.1007/s43440-022-00440-6. Epub 2022 Dec 16.
10
Pharmacogenetics of Antipsychotic Treatment in Schizophrenia.抗精神病药物治疗精神分裂症的药物遗传学。
Methods Mol Biol. 2022;2547:389-425. doi: 10.1007/978-1-0716-2573-6_14.
本文引用的文献
1
Metabolic syndrome with the atypical antipsychotics.代谢综合征与非典型抗精神病药物。
Curr Opin Endocrinol Diabetes Obes. 2010 Oct;17(5):460-6. doi: 10.1097/MED.0b013e32833de61c.
2
Systematic analysis of dopamine receptor genes (DRD1-DRD5) in antipsychotic-induced weight gain.抗精神病药所致体重增加的多巴胺受体基因（DRD1-DRD5）的系统分析。
Pharmacogenomics J. 2012 Apr;12(2):156-64. doi: 10.1038/tpj.2010.65. Epub 2010 Aug 17.
3
DRD2 promoter region variation predicts antipsychotic-induced weight gain in first episode schizophrenia.DRD2 启动子区域变异可预测首发精神分裂症患者抗精神病药物引起的体重增加。
Pharmacogenet Genomics. 2010 Sep;20(9):569-72. doi: 10.1097/FPC.0b013e32833ca24b.
4
Association of HTR2C, but not LEP or INSIG2, genes with antipsychotic-induced weight gain in a German sample.德国样本中 HTR2C 基因与抗精神病药引起的体重增加相关，而 LEP 或 INSIG2 基因则没有相关性。
Pharmacogenomics. 2010 Jun;11(6):773-80. doi: 10.2217/pgs.10.50.
5
Dopamine receptor D2 gene is associated with weight gain in schizophrenic patients under long-term atypical antipsychotic treatment.多巴胺受体 D2 基因与长期使用非典型抗精神病药物治疗的精神分裂症患者的体重增加有关。
Pharmacogenet Genomics. 2010 Jun;20(6):359-66. doi: 10.1097/FPC.0b013e3283397d06.
6
Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs.抗精神病药物代谢副作用的全基因组药物基因组学研究。
Mol Psychiatry. 2011 Mar;16(3):321-32. doi: 10.1038/mp.2010.14. Epub 2010 Mar 2.
7
D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis.D2 受体基因变异与抗精神病药物治疗的临床反应：荟萃分析。
Am J Psychiatry. 2010 Jul;167(7):763-72. doi: 10.1176/appi.ajp.2009.09040598. Epub 2010 Mar 1.
8
G-protein beta3 Subunit Gene 825C/T Polymorphism Is Not Associated with Olanzapine-Induced Weight Gain in Korean Schizophrenic Patients.G 蛋白 β3 亚基基因 825C/T 多态性与韩国精神分裂症患者奥氮平诱导的体重增加无关。
Psychiatry Investig. 2009 Mar;6(1):39-43. doi: 10.4306/pi.2009.6.1.39. Epub 2009 Mar 31.
9
Absence of weight gain association with the HTR2C -759C/T polymorphism in patients with schizophrenia treated with iloperidone.在接受依匹哌唑治疗的精神分裂症患者中，HTR2C-759C/T 多态性与体重增加无关。
Psychiatry Res. 2010 Feb 28;175(3):271-3. doi: 10.1016/j.psychres.2009.03.020. Epub 2009 Dec 31.
10
Effect of dopamine D3 receptor gene polymorphisms and clozapine treatment response: exploratory analysis of nine polymorphisms and meta-analysis of the Ser9Gly variant.多巴胺 D3 受体基因多态性与氯氮平治疗反应的关系：9 种多态性的探索性分析及 Ser9Gly 变异的荟萃分析
Pharmacogenomics J. 2010 Jun;10(3):200-18. doi: 10.1038/tpj.2009.65. Epub 2009 Dec 22.
Zotero 插件